Observational pilot study of breast cancer patients receiving emetogenic chemotherapy with a single dose of Aloxi (palonosetron) 0.25 mg and corticosteroids [ÉTUDE PILOTE OBSERVATIONNELLE CHEZ DES PATIENTES SOUFFRANT D'UN CANCER DU SEIN ET RECEVANT UNE CHIMIOTHÉRAPIE ÉMÉTISANTE TRAITÉES PAR UNE DOSE UNIQUE DE ALOXI (PALONOSÉTRON) 0.25 MG ASSOCIÉE À UNE CORTICOTHÉRAPIE]

Trial Profile

Observational pilot study of breast cancer patients receiving emetogenic chemotherapy with a single dose of Aloxi (palonosetron) 0.25 mg and corticosteroids [ÉTUDE PILOTE OBSERVATIONNELLE CHEZ DES PATIENTES SOUFFRANT D'UN CANCER DU SEIN ET RECEVANT UNE CHIMIOTHÉRAPIE ÉMÉTISANTE TRAITÉES PAR UNE DOSE UNIQUE DE ALOXI (PALONOSÉTRON) 0.25 MG ASSOCIÉE À UNE CORTICOTHÉRAPIE]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jul 2012

At a glance

  • Drugs Palonosetron (Primary) ; Methylprednisolone
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Therabel
  • Most Recent Events

    • 02 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top